Gilead

Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
Six ways to combat pharma price gougingDrug price increases can prove challenging for payers. Here’s six strategies to keep in your arsenal.
5 things to know about Gilead’s new hep C drugGilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.
FDA approves Harvoni for new usesFDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
Top 4 things you need to know about the state of HIV treatmentWhile Gilead works on a “cure,” here are four things managed care executives need to know about the current state of HIV treatment
FDA approves changes to hep C drug label to include new warningsFDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
Gilead sues to stop Actavis' generic bid for LetairisActavis plc on Friday said it filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) seeking approval to market Ambrisentan Tablets, a generic version of Gilead Sciences, Inc.'s Letairis®, a treatment for pulmonary arterial hypertension.
New hep C drugs will strain the system: MD Anderson studyThe cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies is likely to place a tremendous economic burden on the country’s healthcare system, according to a study published in the March 17 issue of the Annals of Internal Medicine.
FDA warns about serious reactions to Harvoni, SovaldiBoth the Food and Drug Administration (FDA) and Harvoni and Sovaldi maker Gilead are warning Hepatitis C patients about serious bradycardia when the drugs are combined with certain other medications.
PBMs, insurers strike deals for Hep C drugsDiscounts and rebates negotiated by some third-party payers are ensuring the place of hepatitis C drugs in their formularies.